Articles Mentioning Biotechnology Stocks

Results 1 - 10 of 343 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology

Investing | November 25, 2014

Should Allergan Investors Stick With Actavis?

Just because you own Allergan doesn't mean you should necessarily own Actavis.

Investing | November 12, 2014

5 Things Actavis plc's Management Wants You to Know

Specialty and generic drugmaker Actavis plc reported another monster quarter last week. Here are five things management wants investors to know going forward.

Investing | November 11, 2014

Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?

Valeant Pharmaceuticals' takeover bid for Allergan has turned hostile in more ways than one.

Investing | November 08, 2014

3 Biotech Stocks to Watch in November

Biotech can be a tough sector for many investors. Here, our analysts share their three favorite picks as we go into November.

Investing | November 06, 2014

Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October

Aegerion Pharmaceuticals is October's worst biotech stock after reporting weaker-than-expected third-quarter results. Find out whether this dip is a buying opportunity or a warning sign of more weakness to come.

Investing | November 05, 2014

Alnylam Pharmaceuticals, Inc. Has This Ratio Right

Alnylam's third-quarter earnings call was all about the pipeline data.

Investing | November 05, 2014

Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza

Actavis posted third-quarter earnings this morning. Here's what you need to know.

Investing | November 05, 2014

5 Things Celgene Corporation's Management Wants You to Know

Following another strong quarterly earnings report, here are five things Celgene's management team would like investors to know.

Investing | October 24, 2014

3 Money-Making Biotech Stocks That Could Go Higher

NPS Pharmaceuticals, ANI Pharmaceuticals, and Insys Therapeutics are expected to see their earnings jump in the coming year.

Investing | October 22, 2014

Celgene Corporation's Earnings Preview: Pay Attention to New Kids

Revlimid might be the flagship, but growth will come from the newer drugs.

Results 1 - 10 of 343 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology